ES2652495T3 - Método para detectar anticoagulantes lúpicos - Google Patents
Método para detectar anticoagulantes lúpicos Download PDFInfo
- Publication number
- ES2652495T3 ES2652495T3 ES12800902.4T ES12800902T ES2652495T3 ES 2652495 T3 ES2652495 T3 ES 2652495T3 ES 12800902 T ES12800902 T ES 12800902T ES 2652495 T3 ES2652495 T3 ES 2652495T3
- Authority
- ES
- Spain
- Prior art keywords
- blood
- sample
- time
- coagulation
- blood sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Rehabilitation Therapy (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Un método para detectar anticoagulantes lúpicos, comprendiendo el método las siguientes etapas (A), (B) y (C): (A) añadir una composición solución tampón que contiene factores de coagulación sanguínea a cada una de una muestra de sangre y una muestra diluida de la muestra de sangre antes de la medición o en el momento de la medición del tiempo de coagulación sanguínea; (B) medir los tiempos de coagulación sanguínea para las diversas muestras de la etapa (A); y (C) comparar los tiempos de coagulación sanguínea para las diversas muestras obtenidas en la etapa (B), donde cuando la relación (tiempo de coagulación de la muestra diluida) / (tiempo de coagulación de la muestra de sangre) es menor de un valor de corte calculado a partir de valores medidos de plasmas de personas sanas sin anormalidad de coagulación, la muestra de sangre se considera que es positiva para anticoagulante lúpico.
Description
Como se enumera en la Tabla 4, en los plasmas de pacientes deficientes en factor de coagulación (FVIII y FIX) en los que se niega la presencia de AL, los valores resultado fueron mayores de o iguales al valor de corte en el ensayo de cribado de TTPA, de manera que es difícil la discriminación de la positividad de AL. Por otro lado, en el ensayo de TVVRd, el ensayo de mezcla, y los Inventos 1 y 2, los valores resultado eran todos negativos. El método de la presente invención implica un sistema en el que los factores de coagulación se complementan a un plasma de ensayo; sin embargo, puesto que el método incluye un proceso de comparación de los valores obtenidos antes y después de la dilución, los resultados obtenidos en un estado en el que simplemente los factores de coagulación son deficientes, y los resultados en el caso que es positivo a inhibidor no son ambiguos. La discriminación se puede hacer claramente como en el caso del ensayo de TVVRd o el ensayo de mezcla.
Como se enumera en la Tabla 5, en el grupo de administrado con heparina/no AL, los valores resultado en siete ejemplos de ocho ejemplos son todos mayores de o iguales al valor de corte en el ensayo de cribado de TTPA, de manera que es difícil la discriminación a partir de la positividad de AL. Además, en el ensayo de TVVRd, dos ejemplos de ocho ejemplos mostraron falsa positividad (en la tabla, indicado como “positivo*”). Por otro lado, los resultados eran todos negativos en las Invenciones 1 y 2.
Claims (1)
-
imagen1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011135173 | 2011-06-17 | ||
| JP2011135173 | 2011-06-17 | ||
| PCT/JP2012/065433 WO2012173259A1 (ja) | 2011-06-17 | 2012-06-15 | ループスアンチコアグラントの検出方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2652495T3 true ES2652495T3 (es) | 2018-02-02 |
Family
ID=47357237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12800902.4T Active ES2652495T3 (es) | 2011-06-17 | 2012-06-15 | Método para detectar anticoagulantes lúpicos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9977038B2 (es) |
| EP (1) | EP2722674B1 (es) |
| JP (1) | JP6028314B2 (es) |
| KR (1) | KR101979865B1 (es) |
| CA (1) | CA2839117C (es) |
| ES (1) | ES2652495T3 (es) |
| WO (1) | WO2012173259A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE540132C2 (sv) | 2014-05-22 | 2018-04-10 | Zafena Ab | Analysmetod för bestämning av antikoagulanter i blod eller blodplasma |
| JP6499488B2 (ja) * | 2015-03-31 | 2019-04-10 | 学校法人東日本学園 | 凝固時間の測定方法、ループスアンチコアグラントの存否の判定方法及びループスアンチコアグラント検出用試薬キット |
| JP6837851B2 (ja) * | 2017-01-31 | 2021-03-03 | シスメックス株式会社 | 血液検体の判定方法、並びに血液検体の分析のための装置及びコンピュータプログラム |
| JP6873833B2 (ja) * | 2017-06-09 | 2021-05-19 | シスメックス株式会社 | 血液検体の判定方法、血液検体分析装置及びコンピュータプログラム |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5543145A (en) * | 1984-09-17 | 1996-08-06 | Baxter International, Inc. | Pharmaceutical composition and method for the suppression of factor VIII inhibitor production |
| JPH0650999B2 (ja) | 1988-09-12 | 1994-07-06 | 日本商事株式会社 | 血液凝固因子安定化法 |
| US4877741A (en) | 1988-10-24 | 1989-10-31 | The United States Of America As Represented By The Secretary Of The Air Force | Treatment of human plasma with brown recluse spider toxin to emulate a lupus anticoagulant |
| EP1562047B1 (en) * | 2004-02-06 | 2008-05-14 | Sysmex Corporation | Reagent kit for detecting lupus anticoagulant |
| US7932021B2 (en) | 2005-07-28 | 2011-04-26 | American Diagnostica, Inc. | Lupus anticoagulant testing |
| CN101221189B (zh) | 2007-01-12 | 2012-08-15 | 上海太阳生物技术有限公司 | 一种用于测定活化部分凝血活酶时间aptt的体外诊断试剂盒 |
| ES2528592T3 (es) | 2008-06-18 | 2015-02-10 | Sekisui Medical Co., Ltd. | Método para determinar la causa de la prolongación del tiempo de coagulación sanguínea |
-
2012
- 2012-06-15 WO PCT/JP2012/065433 patent/WO2012173259A1/ja active Application Filing
- 2012-06-15 KR KR1020137033381A patent/KR101979865B1/ko active IP Right Grant
- 2012-06-15 ES ES12800902.4T patent/ES2652495T3/es active Active
- 2012-06-15 US US14/127,026 patent/US9977038B2/en active Active
- 2012-06-15 CA CA2839117A patent/CA2839117C/en active Active
- 2012-06-15 JP JP2013520612A patent/JP6028314B2/ja active Active
- 2012-06-15 EP EP12800902.4A patent/EP2722674B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2839117A1 (en) | 2012-12-20 |
| CA2839117C (en) | 2019-09-17 |
| US9977038B2 (en) | 2018-05-22 |
| JP6028314B2 (ja) | 2016-11-16 |
| KR101979865B1 (ko) | 2019-05-17 |
| CN103649758A (zh) | 2014-03-19 |
| US20140127725A1 (en) | 2014-05-08 |
| EP2722674A1 (en) | 2014-04-23 |
| WO2012173259A1 (ja) | 2012-12-20 |
| KR20140034230A (ko) | 2014-03-19 |
| EP2722674B1 (en) | 2017-11-29 |
| EP2722674A4 (en) | 2015-02-25 |
| JPWO2012173259A1 (ja) | 2015-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Martinuzzo et al. | Frequent false‐positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin | |
| ES2652495T3 (es) | Método para detectar anticoagulantes lúpicos | |
| Merriman et al. | Rivaroxaban and false positive lupus anticoagulant testing | |
| Mani et al. | Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions | |
| Antovic et al. | Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting | |
| JP4505045B2 (ja) | 血液凝固時間の延長原因の判定法 | |
| BR112015004878A2 (pt) | dispositivo e método para determinar se as condições predeterminadas para medir um primeiro parâmetro fisiológico de um indivíduo são atendidas, e, vestimenta para ser vestida pelo indivíduo | |
| BR112014010718A2 (pt) | métodos e sistemas para detecção de analito em amostra | |
| Chojnowski et al. | Effects of rivaroxaban therapy on ROTEM coagulation parameters in patients with venous thromboembolism | |
| Guzmán-Uribe et al. | Thrombosis in leukemia: incidence, causes, and practical management | |
| Monteyne et al. | Interference of DOAC stop and DOAC remove in the thrombin generation assay and coagulation assays | |
| Blaine et al. | Viscoelastic monitoring to guide the correction of perioperative coagulopathy and massive transfusion in patients with life-threatening hemorrhage | |
| Zalewski et al. | Rivaroxaban concentration in patients with deep vein thrombosis who reported thrombus progression or minor hemorrhagic complications: first Polish experience | |
| BR112014027490A2 (pt) | método de detecção eletroquímica | |
| Caldwell | Management of coagulopathy in liver disease | |
| CA2883260C (en) | Composition for use as an abnormal coagulation control plasma in in vitro assays | |
| Hamali et al. | Elevated levels of pro-coagulant microvesicles in children in-steady state sickle cell disease | |
| Abreu et al. | Models for releasing the lupus anticoagulant test | |
| BR112014027411A2 (pt) | detecção de ativação do complemento | |
| Geddings et al. | Comment on “Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients” | |
| Potze et al. | Issues with monitoring of unfractionated heparin in cirrhosis | |
| EA201690995A1 (ru) | Способы обнаружения и количественного анализа циркулирующих эндотелиальных клеток | |
| BR112015032567A2 (pt) | supressor de erro de preenchimento para uma medição de analito determinada a partir de um tempo de amostragem especificado derivado de uma característica física detectada da amostra contendo o analito | |
| Pengo | Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma: comment | |
| Atalay et al. | sEPCR Levels in Chronic Myeloproliferative Diseases and Their Association with Thromboembolic Events: A Case-Control Study |